InMed Pharmaceuticals Inc (INM)
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer’s Disease Program
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer’s Disease Program
Change in holdings of interested parties/officers
Arcus Biosciences - Arcus Chief Operations Officer Departs for Role as CEO
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES-Davidi Ishay
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
TWO Determines Unsolicited Proposal from CrossCountry Mortgage is a “Company Superior Proposal”
Mobileye Secures Major DMS Production Program with Leading U.S. Automaker
Ford and Major League Baseball Unite to Celebrate America’s Pastime and the People Who Power It